EMEA-002468-PIP04-18
Key facts
Active substance |
belantamab mafodotin
|
Therapeutic area |
Oncology
|
Decision number |
P/0347/2019
|
PIP number |
EMEA-002468-PIP04-18
|
Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of Multiple Myeloma
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
GlaxoSmithKline Trading Services Limited
Tel. +1 4388998201 |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|